Licensing status

Publication and contact information

Autoimmune disease

Multiple sclerosis (MS)

BET bromodomain proteins

In vitro and cell culture studies suggest selective inhibitors of BET bromodomain proteins could be useful for promoting myelin regeneration in MS. BET bromodomain proteins contain two bromodomains, BRD1 and BRD2. In vitro structure-guided design studies identified a class of compounds selective for BRD1 over BRD2. In a cell culture assay of oligodendrocyte maturation, the best BRD1-selective compound increased differentiation and myelin production compared with nonselective inhibitors that target BRD1 and BRD2. Next steps include evaluating the compounds in rodent models of remyelination.
Biogen Idec Inc.'s BIIB033, a mAb that promotes remyelination, is in Phase II testing in MS.
Inception 5 Inc. has preclinical compounds to promote oligodendrocyte maturation in development for MS.

SciBX 7(29); doi:10.1038/scibx.2014.852
Published online July 31, 2014

Patent pending; available for licensing

Gacias, M. et al. Chem. Biol.; published online June 17, 2014;
Contact: Ming-Ming Zhou, Icahn School of Medicine at Mount Sinai,
New York, N.Y.

Contact: Patrizia Casaccia, same affiliation as above